the authors also clarify that the consequences of actual weight-based dosing of chemotherapy in the morbidly obese have not been adequately studied and hence remain unknown. Second, this guideline provides little advice on how to determine chemotherapy dosage in obese patients who are receiving concomitant chemotherapy and radiation, particularly to the thorax. With concomitant therapy, it is tenable that surrounding vital structures can sustain notable damage as a result of higher chemotherapy doses that markedly
P = .006) when chemotherapy dosage is based on ideal weight heighten concerns that underdosing, not actual weight-based dosing, accounts for the poorer outcomes among obese patients with cancer. 2, 3 Furthermore, the fact that rates of obesity are reaching an all-time high in the United States and in other parts of the world makes this recent practice guideline timely and relevant.
Introduction
In 2012, the American Society of Clinical Oncology issued a practice guideline that urged health care professionals to "routinely use an obese patient's actual body weight, rather than an ideal body weight or other estimate, to calculate the appropriate dose of nearly all chemotherapy drugs." 1 This guideline described how 40% of obese patients are underdosed because of healthcare providers' unsubstantiated fears of undue toxicity from chemotherapy dosing based on actual weight. Observations that obese patients experience acceptable rates of myelosuppression when the chemotherapy dosage is based on actual weight but that, for example, obese colorectal patients manifest worse progression-free survival (hazard ratio = 1.21; 95% confidence interval [ potentiate the effects of radiation and, in turn, result in an unacceptable adverse-event profile. Although previous studies have examined outcomes in obese patients with thoracic malignancies and report that these patients can do well, it remains unclear whether these favorable outcomes occurred even in patients who had a BMI of 40 or greater and who were prescribed full-dose chemotherapy. 5, 6 The purpose of this case series was to augment the limited available data on the concomitant administration of thoracic radiation and chemotherapy in morbidly obese patients. This single-institution, descriptive case series explored the following questions: (1) What percentage of patients receiving concomitant chemotherapy and radiation are morbidly obese? (2) Do morbidly obese patients who initiate full-dose chemotherapy based on actual weight in conjunction with radiation suffer severe adverse events? (3) Do morbidly obese patients who receive an initial chemotherapy dose reduction in conjunction with radiation also experience severe adverse events?
Methods
The Mayo Clinic Institutional Review Board reviewed and approved this study prior to the review of medical records. Thereafter, the study team obtained a list of all patients with esophageal or lung cancer who had received radiation with curative intent at the Mayo Clinic in Rochester, Minnesota, from 1999 through the beginning of 2013. This list was culled further by one of the authors (EKS) to include only patients who had a BMI of 40 or greater within 2 weeks of starting concomitant chemotherapy and radiation. This focus on patients with this BMI was prompted by the fact that the recent chemotherapy dosing guideline from the American Society of Clinical Oncology had outlined a gap in clinical data from this group of patients, as discussed above, and by well-accepted definitions of morbid obesity. 7, 8 Each patient's medical record was reviewed for patient-and cancer-related demographics, including baseline body surface area as calculated with methodology from Gehan and George, 9 baseline comorbidities, performance score, hemoglobin and albumin levels, type and dose of chemotherapy administered, dose of radiation administered, the number and type of unplanned hospitalizations that occurred within 30 days of completion of concomitant chemotherapy and radiation, other cancer treatment rendered (eg, surgical extirpation of the tumor), and date of patient's last follow-up or death. Date of cancer recurrence was not captured as monitoring for recurrent disease varied widely within this small cohort, thus making such data difficult to interpret. This review was conducted by one of the authors (KP) with accuracy checked by another (AJ).
The Charlson morbidity index 10 was calculated for each patient. Survival data were censored as appropriate. Data are presented descriptively, rounded as appropriate, and organized and graphed with JMP Software, (SAS Institute, Cary, North Carolina).
Results

Incidence and Baseline Demographics
Of note, 1 patient with lung cancer and 1 patient with esophageal cancer received full-dose carboplatin/ pemetrexed and docetaxel/oxaliplatin/capecitabine, respectively, prior to combined chemotherapy and radiation. This chemotherapy was well tolerated, although the lung cancer patient developed pneumonia that was managed as an outpatient.
Chemotherapy Dosing With Concomitant Radiation
Ten of 16 patients received an initial chemotherapy dose-reduction. Only 1 patient within the cohort received a subsequent dose escalation, and this patient had been given a previous dose-reduction.
Adverse Events
Among the 6 patients who received full-dose initial chemotherapy, 2 experienced major adverse events. Similarly, among the 10 patients who received an initial dose reduction, 4 experienced major adverse events, including 1 death. This patient was hospitalized with heart block and renal failure, had a pacemaker placed, and received intravenous fluids. These steps led to an improvement in his renal function, and he was fully ambulatory prior to discharge from the hospital. However, the following day while at home, he experienced a syncopal episode, became pulseless, and failed to respond to resuscitation attempts in the emergency department.
Follow-up
Among the 10 esophageal cancer patients, 7 went on to have their cancer resected. Among the 6 lung cancer patients, 2 had a cancer resection. At the time of this report, 10 patients had died and 6 were alive at the last follow-up (Figure) . 
Discussion
The goals of this study were two-fold. First, we sought to explore the incidence of morbid obesity among thoracic oncology patients who were candidates for concomitant, potentially curative chemotherapy and radiation. Second, we attempted to gain an understanding of treatment-related morbidity. As relevant to the first goal, our data underscore the point alluded to in the recent American Society of Clinical Oncology guideline, namely, that garnering data on morbidly obese patients with cancer is challenging because these patients represent only a small subgroup of cancer patients. 1 At our institution, among lung and esophageal cancer patients who received potentially curative therapy with radiation, less than 1% of the entire cohort met our study criteria. This low percentage is particularly surprising in view of the fact that obesity is a risk factor for some types of cancer, such as esophageal cancer. 11 This small percentage, which included only 16 patients, emphasizes the limitations of drawing firm conclusions on patient management. Nonetheless, our data do allow for some preliminary suggestions. First, 4 of 10 esophageal cancer patients who had an initial chemotherapy dose reduction suffered fairly severe adverse events, and 1 of these patients died. This severe toxicity raises concerns of what might have occurred had these patients not received a dose reduction and speaks in favor of reducing the dose of chemotherapy, based on clinical judgment, patient comorbidities, and other clinical circumstances. Thus, clinicians cannot be faulted for sometimes reducing the dose of chemotherapy when treating morbidly obese patients. As further support of this approach, within the cohort as a whole, the fact that only 1 patient was administered a chemotherapy dose escalation after the first chemotherapy cycle further suggests that the initial dosing of chemotherapy, which included a dose reduction in 10 of 16 patients, seems to have been appropriate for these morbidly obese patients. Second, concomitant chemotherapy options have slowly evolved over the years to include ostensibly better-tolerated chemotherapy regimens, particularly for the treatment of esophageal cancer. 12 The fact that some patients in this cohort received a combination of weekly carboplatin and paclitaxel without a dose reduction and with minimal major adverse events suggests that newer regimens might be more appropriate in this setting and may even be able to be administered at full dose. 
